• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Owens & Minor Inc.

    10/15/24 7:01:02 AM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email
    8-K
    OWENS & MINOR INC/VA/ false 0000075252 0000075252 2024-10-11 2024-10-11

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 11, 2024

     

     

    OWENS & MINOR, INC.

    (Exact name of Registrant as specified in charter)

     

     

     

    Virginia   001-09810   54-1701843
    (State or other jurisdiction
    of incorporation)
      (Commission
    file number)
      (I.R.S. employer
    identification no.)

     

    9120 Lockwood Blvd.,  
    Mechanicsville, Virginia   23116
    (Address of principal executive offices)   (Zip code)

     

    Post Office Box 27626,  
    Richmond, Virginia   23261-7626
    (Mailing address of principal executive offices)   (Zip code)

    Registrant’s telephone number, including area code (804) 723-7000

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $2 par value per share   OMI   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

     

     

     


    Item 8.01

    Other Events.

    As previously announced on July 22, 2024, Owens & Minor, Inc., a Virginia corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement” and the transactions contemplated thereby, the “Merger”) by and among the Company, Rotech Healthcare Holdings Inc., a Delaware corporation (“Rotech”), Hitchcock Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of the Company and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the equity holders of Rotech.

    On October 11, 2024, the Company and Rotech each received a request for additional information and documentary materials (a “Second Request”) from the Federal Trade Commission (the “FTC”) in connection with the FTC’s review of the Merger. The effect of a Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), until 30 days after each of the Company and Rotech has substantially complied with the Second Request issued to it, unless that period is extended voluntarily by the parties or terminated earlier by the FTC.

    Completion of the Merger remains subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of the other closing conditions specified in the Merger Agreement. The Company continues to work constructively with the FTC in its review of the Merger and expects that the Merger will be completed in the first half of 2025, subject to satisfaction or waiver of the closing conditions, including receipt of required regulatory approvals.

    Forward Looking Statements

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the proposed Merger and the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. The Company cautions readers of this communication that such “forward looking statements,” wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward-looking statements.”

    Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the inability to complete the proposed Merger due to the failure to obtain approval of Rotech’s stockholders for the proposed Merger or the failure to satisfy other conditions to completion of the proposed Merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed Merger; risks related to disruption of management’s attention from the Company’s ongoing business operations due to the proposed Merger; the effect of the announcement of the proposed Merger on the Company’s relationships with its customers, suppliers and other third parties, as well as it operating results and business generally; the risk that the proposed Merger will not be consummated in a timely manner; exceeding the expected costs of the Merger; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected; the risk that the combined company may be unable to achieve synergies or it may take longer than expected to achieve those synergies.

    Additional factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2023 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        OWENS & MINOR, INC.
    Date: October 15, 2024     By:  

    /s/ Heath H. Galloway

        Name:   Heath H. Galloway
        Title:   Executive Vice President, General Counsel & Corporate Secretary
    Get the next $OMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    11/3/2025$4.00Buy → Neutral
    UBS
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    More analyst ratings

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/10/25 9:43:55 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    4/7/25 8:21:15 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity

    The Transaction Includes the Owens & Minor Brand, and the Remaining Company Will Become Accendra Health Completes the Company's Transformation into a Pure Play Leader in the Home-Based Care Market Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity and is renaming the publicly traded parent company Accendra Health, Inc. "Today's announcement marks an inflection point in the strategic transformation of Owens & Minor into Accendra Health, a leading nationwide pure play home based care platform. The completion of the sale of the P&HS segment enables the Comp

    12/31/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.

    Accendra Health To Trade Under the "ACH" Symbol on the New York Stock Exchange Owens & Minor, Inc. (NYSE:OMI) ("the Company") today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31, 2025. The name change affects only the name of the parent corporation and is intended to better reflect the Company's strategic direction and future organizational focus as a leader in the home-based care market. The Company will continue to use and operate under the Apria and Byram Healthcare brands. "The renaming of our organization is another milestone in the strategic transformation of our company as a leading, pure play home-based care busin

    12/18/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025

    Owens & Minor, Inc. (NYSE:OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global Healthcare Conference On Tuesday, December 2, 2025, Ed Pesicka, the Company's President and Chief Executive Officer, and Will Parrish, the Company's Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and host one-on-one investor meetings at the conference in Miami, Florida. Please visit the "Events & Presentations" section of the "Investor Relations" page on the Owens & Minor website available at https://investors.owens-minor.com at least

    12/2/25 7:00:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CEO P&HS Long Andrew G gifted 47,908 shares, decreasing direct ownership by 18% to 214,064 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    11/20/25 4:11:13 PM ET
    $OMI
    Medical Specialities
    Health Care

    EVP & CFO Leon Jonathan A covered exercise/tax liability with 4,265 shares, decreasing direct ownership by 2% to 218,522 units (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    9/24/25 4:07:31 PM ET
    $OMI
    Medical Specialities
    Health Care

    Large owner Coliseum Capital Management, Llc bought $8,099,544 worth of shares (1,537,852 units at $5.27) (SEC Form 4)

    4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

    8/14/25 8:23:48 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    SEC Filings

    View All

    Amendment: Owens & Minor Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)

    1/5/26 4:05:19 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/31/25 4:15:43 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

    12/18/25 4:18:47 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Owens & Minor downgraded by UBS with a new price target

    UBS downgraded Owens & Minor from Buy to Neutral and set a new price target of $4.00

    11/3/25 9:08:29 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor upgraded by Citigroup with a new price target

    Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

    7/19/24 7:41:01 AM ET
    $OMI
    Medical Specialities
    Health Care

    Leerink Partners initiated coverage on Owens & Minor with a new price target

    Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

    2/26/24 8:10:20 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    11/12/24 10:32:12 AM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/13/24 5:12:07 PM ET
    $OMI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

    SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

    2/12/24 5:29:41 PM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

    Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

    6/22/22 6:50:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    $OMI
    Financials

    Live finance-specific insights

    View All

    Owens & Minor Reports Third Quarter 2025 Financial Results

    Signed Definitive Agreement for the Sale of Products & Healthcare Services Segment Transaction Positions the Company as a Pure-Play Home-Based Care Business Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the Company's continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations. "Our recent announcement on the sale of our Products & Healthcare Services segment is another meaningful step in our strategy to pivot our focus to the more attractive home-based care space. We are keenly focused on reshaping ou

    10/30/25 4:05:00 PM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Date and Time Change of Third Quarter 2025 Financial Results and Conference Call

    Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the third quarter of 2025 on Thursday, October 30, 2025, after trading ends on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 5:00 p.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast c

    10/16/25 6:30:00 AM ET
    $OMI
    Medical Specialities
    Health Care

    Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for $375mm in Cash and a Retained Equity Stake

    Transforms Owens & Minor into a Pure Play Market Leader in the Home-Based Care Market 5% Retained Equity Stake Provides Ability to Realize Future Value Creation Under Platinum Equity Preserves Tax Attributes in Excess of $150 Million Owens & Minor, Inc. (NYSE:OMI) today announced that it has entered into a definitive agreement for the sale of the Company's Products & Healthcare Services (P&HS) segment to Platinum Equity. Over the last several years, Owens & Minor has been strategically moving towards expanding its leadership position in the very attractive home-based care space. This transaction will allow the Company to focus on a simpler business model and allow for a more appropria

    10/7/25 4:15:00 PM ET
    $OMI
    Medical Specialities
    Health Care